Eyeonix AIQ, Inc. filed a Form 8-K on November 3, 2026, disclosing that its wholly owned subsidiary, Eyeonix MedAIQ, Inc., entered into a Memorandum of Understanding on October 30, 2026, with Eyeonix S.A. of Greece regarding the proposed acquisition of the COMMAND HEALGRID software source code.

Key Highlights

  • MOU date: The Memorandum of Understanding was signed on October 30, 2026, between Eyeonix MedAIQ, Inc. and Eyeonix S.A., a company organized under the laws of Greece.
  • Asset involved: The proposed acquisition covers the source code for software known as COMMAND HEALGRID, developed by Eyeonix Greece.
  • Consideration: As consideration, the Company would issue 30,600,000 shares of its common stock to Eyeonix Greece.
  • Development responsibility: Under the proposed terms, Eyeonix MedAIQ would assume responsibility for the Asset's ongoing development.
  • Expected timeline: According to the filing, "The transaction is expected to finalize in this calendar year."
  • Emerging growth company: Eyeonix AIQ, Inc. identified itself as an emerging growth company in the filing.

Eyeonix MedAIQ's Proposed Acquisition of COMMAND HEALGRID from Eyeonix Greece

According to the Form 8-K filed with the SEC on November 3, 2026, Eyeonix MedAIQ, Inc., described in the filing as a Wyoming corporation and wholly owned subsidiary of Eyeonix AIQ, Inc., entered into a Memorandum of Understanding with Eyeonix S.A., a company organized under the laws of Greece, on October 30, 2026. The MOU concerns the proposed acquisition of the source code for software called COMMAND HEALGRID, which the filing states was developed by Eyeonix Greece.

The filing describes the proposed structure of the transaction: Eyeonix Greece would transfer to Eyeonix MedAIQ all of its rights in the Asset, and Eyeonix MedAIQ would assume responsibility for the Asset's ongoing development. As consideration for this transfer, Eyeonix AIQ, Inc. would issue to Eyeonix Greece 30,600,000 shares of its common stock. The filing does not state a per-share price or total dollar valuation for the transaction.

The filing notes that the transaction is expected to finalize within the current calendar year. The report also includes a forward-looking statements caution, noting that statements about "the proposed transaction, including its terms, timing and completion" involve risks and uncertainties and that "actual results may differ materially." The filing was signed by George Athanasiadis, identified as CEO/Director of Eyeonix AIQ, Inc. The company's securities registered under Section 12(b) of the Act are listed as N/A in the filing's registered-securities table, with the ticker EAIQ appearing in the registrant's name line on the cover page.

What Was Disclosed

Eyeonix AIQ, Inc. disclosed a Memorandum of Understanding under which its subsidiary Eyeonix MedAIQ, Inc. proposes to acquire the COMMAND HEALGRID software source code from Eyeonix S.A. of Greece in exchange for 30,600,000 shares of the Company's common stock, with finalization expected within the current calendar year.